Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry

Industry sponsor intelligence

AmgenClinical Pipeline.

Lead-sponsor view of Amgen's indexed peptide studies, development phases, active programs, completed work and recent registry changes.

Total
29
Recruiting
6
Active
9
Completed
14
Results posted
4
Avg enrollment
1,090

Pipeline overview

Programs by phase and activity.

Velocity

Amgen trials by start year

Study start year · indexed snapshot

141174020092009: 1 trials2010: 0 trials2011: 0 trials20122012: 0 trials2013: 1 trials2014: 0 trials20152015: 0 trials2016: 0 trials2017: 0 trials20182018: 0 trials2019: 0 trials2020: 1 trials20212021: 1 trials2022: 0 trials2023: 1 trials20242024: 5 trials2025: 14 trials20262026: 5 trials

Development

Trials by phase

Early Phase 10
Phase 114
Phase 24
Phase 311
Phase 40
ProductStudiesEarly / IPhase IIPhase IIIPhase IVActive
Maridebart cafraglutide →2714310015
Teriparatide →201100
Glucagon →100101

Active peptide trials

In motion now.

Showing 10 of 15 studies

Completed trials

Finished registry records.

Showing 10 of 14 studies

Search sponsor records

All Amgen studies.

This page groups studies where Amgen is listed as the lead industry sponsor. Collaborator-only records are not included in the count.

29 matching studies

Recent updates

Latest registry movement.

NCT07037433Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityJul 24, 2026NCT07575399Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)Jul 23, 2026NCT07717814A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or ObesityJul 21, 2026NCT07523711Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityJul 20, 2026NCT07313761A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous PresentationsJul 16, 2026NCT07684144Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)Jul 6, 2026NCT07684235Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)Jul 6, 2026NCT07037459Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityJul 2, 2026NCT07441252A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightJun 18, 2026NCT07226778Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) PresentationsJun 17, 2026